Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00730821
Recruitment Status : Completed
First Posted : August 8, 2008
Last Update Posted : August 21, 2009
Information provided by:
Boehringer Ingelheim

Brief Summary:

The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule.

Secondary objectives are the collection of antitumor efficacy data, the determination of pharmacokinetic parameters of BIBF 1120 and BIBW 2992, and if data allow the determination of the pharmacokinetic influence of BIBW 2992 on BIBF 1120 and vice versa.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: BIBW 2992 Drug: BIBF 1120 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Primary Purpose: Treatment
Official Title: A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 With BIBF 1120 in Patients With Advanced Solid Tumors
Study Start Date : January 2007
Actual Primary Completion Date : August 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: BIBW 2992 Drug: BIBF 1120

Primary Outcome Measures :
  1. The primary endpoint of this trial is the safety of the combination of BIBW 2992/BIBF 1120 when administered concomitantly, and this is assessed by the dose limiting toxicity [ Time Frame: Until undue toxicity or progressive disease. ]

Secondary Outcome Measures :
  1. Pharmacokinetics, Objective tumor response. [ Time Frame: Until undue toxicity or progressive disease. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients with confirmed diagnosis of advanced, non-resectable and/or metastatic solid tumors, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment.
  2. Age 18 years or older.
  3. Life expectancy of at least three (3) months.
  4. Written informed consent that is consistent with ICH-GCP guidelines.
  5. Eastern Cooperative Oncology Group performance score 0, 1or 2.
  6. Patients recovered from any therapy-related toxicities from previous chemo-,hormone-, immuno-, or radiotherapies to CTC <= Grade 1.
  7. Patients must have recovered from previous surgery.

Exclusion Criteria:

  1. Active infectious disease.
  2. Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea.
  3. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.
  4. Patients with untreated or symptomatic brain metastases. Patients with treated, asymptomatic brain metastases are eligible if there has been no change in brain disease status for at least four (4) weeks, no history of cerebral edema or bleeding in the past four (4) weeks and no requirement for steroids or anti-epileptic therapy.
  5. Cardiac left ventricular function with resting ejection fraction <50%.
  6. Absolute neutrophil count (ANC) less than 1500/mm3.
  7. Platelet count less than 100,000/mm3.
  8. Bilirubin greater than 1.5 mg/dl (>26 ¿mol /L, SI unit equivalent).
  9. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than two and a half times the upper limit of normal (2.5 X ULN ).
  10. Serum creatinine greater than 1.5 mg/dl (>132 ¿mol/L, SI unit equivalent).
  11. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception.
  12. Pregnancy or breast-feeding.
  13. Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (including LHRH agonists, megestrol acetate, or other hormones taken for breast cancer or prostate cancer); participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study. Treatment with bisphosphonates is allowed.
  14. Treatment with an EGFR- or HER2 inhibiting drug within the past 4 weeks before start of therapy or concomitantly with this study (2 weeks for trastuzumab).
  15. Patients unable to comply with the protocol.
  16. Active alcohol or drug abuse.
  17. Patients who require therapeutic anticoagulation or antiplatelet therapy [except treatment with Aspirin (Acetylsalicylic Acid)].
  18. Patients with history of haemorrhagic or thrombotic events (including transient ischemic attacks) in the past 12 months. Known inherited predisposition to bleeding or thrombosis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00730821

United States, Arizona
1239.1.3 Boehringer Ingelheim Investigational Site
Scottsdale, Arizona, United States
United States, Florida
1239.1.1 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
United States, Michigan
1239.1.2 Boehringer Ingelheim Investigational Site
Detroit, Michigan, United States
United States, Nebraska
1239.1.4 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT00730821     History of Changes
Other Study ID Numbers: 1239.1
First Posted: August 8, 2008    Key Record Dates
Last Update Posted: August 21, 2009
Last Verified: August 2009

Additional relevant MeSH terms:
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action